Novel method for prediction of cardiovascular disease risk in type 2 diabetes
OwnerMark B. Zimeringinventor
Life of this patent
Estimating the term…
Abstract
The invention provides a method for diagnosing an increased risk of cardiovascular disease (CVD, including coronary heart disease (CHD)) in patients with type 2 diabetes comprising detecting basic fibroblast growth factor (bFGF) in a sample from the patient, an increased level of bFGF being indicative of increased risk of CHD, thereby diagnosing an increased risk of CHD in diabetic patients.
Claims19
A method for diagnosing an increased risk of cardiovascular disease (CVD) in patients with type 2 diabetes comprising detecting basic fibroblast growth factor (bFGF) in a sample from the patient, an increased level of bFGF being indicative of increased risk of CHD, thereby diagnosing an increased risk of CHD in diabetic patients.
A method for diagnosing an increased risk of CVD in patients with type 2 diabetes comprising detecting basic fibroblast growth factor (bFGF) in a sample from the patient, the level of bFGF is selected from the group consisting of
- a. greater than or equal to 50 pg/ml;
- b. greater than or equal to 45 pg/ml;
- c. greater than or equal to 40 pg/ml;
- d. greater than or equal to 35 pg/ml;
- e. greater than or equal to 30 pg/ml;
- f. greater than or equal to 25 pg/ml;
- and
- g. greater than or equal to 20 pg/ml;
- the level of bFGF of any of a-g being indicative of increased risk of CVD, thereby diagnosing an increased risk of CVD in diabetic patients.
A method for treating CVD in patients with type 2 diabetes comprising administering to the subject an effective amount of an antibody or fragment thereof that recognizes and binds basic fibroblast growth factor (bFGF) in a subject, thereby treating CVD.
Dependencies are inferred from the claim text.